Profil
Sandra Ramos-Alves currently works at Mirati Therapeutics, Inc., as President, Treasurer & Director from 2024, Rayzebio, Inc., as Treasurer, Director & Vice President from 2024, Karuna Therapeutics, Inc., as President, Treasurer & Director from 2024, and Turning Point Therapeutics, Inc., as Chief Executive & Financial Officer from 2022.
Postes actifs de Sandra Ramos-Alves
| Sociétés | Poste | Début |
|---|---|---|
| TURG POIN | Chief Executive Officer | 17/08/2022 |
| MIRATI THERAPEUTICS | President | 23/01/2024 |
| RAYZEBIO, INC. | Director/Board Member | 26/02/2024 |
| KARA THER | President | 18/03/2024 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RAYZEBIO, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Karuna Therapeutics, Inc.
 Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. | Health Technology |
